In a trial in mice, the spray offered protection against SARS-CoV-2 pseudotyped virus for up to 10 hours, according to Eureka Therapeutics. Results were published on the preprint server bioRxiv.

InvisiMask provides an intranasal application of a proprietary antibody thought to be prophylactic against COVID-19. It is designed to neutralize the novel coronavirus in airborne droplets and particles that enter the nasal cavity.

The antibodies were engineered with a proprietary adhesion technology developed to increase retention on respiratory mucosal surfaces, Eureka noted. The spray can also be both stored and used at room temperature.

Eureka is currently preparing to file an investigational new drug application with the U.S. Food and Drug Administration in order to conduct a clinical trial of the nasal spray.

Global health R&D stalls as resources are redirected to COVID-19
The current coronavirus pandemic has set back progress in research and development (R&D) on neglected diseases and other long-standing global health challenges...

Various updates for Pfizer, BioNTech COVID-19 vaccine post-EUA
Various announcements and updates regarding the Pfizer-BioNTech COVID-19 vaccine were made during the weekend and on Monday, December 14. These included...

FDA issues EUA for Pfizer, BioNTech COVID-19 vaccine
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine. The move comes after...

Pfizer, BioNTech's COVID-19 vaccine shows 95% efficacy
In a trial of more than 40,000 participants, Pfizer-BioNTech's COVID-19 vaccine showed a 95% efficacy against the SARS-CoV-2 virus, according to results...